CALCIUM RECEPTOR ANTAGONISTS

wherein R is optionally substituted aryl group or optionally substituted heteroaryl group; R is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R is hydrogen atom, C1-6 alkyl group and the like; R and R are each C1-6 alkyl group and the like; R is optionally substituted aryl group or optionally substituted heteroaryl group; X , X and X are each C1-6 alkylene group and the like; and X and X are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.